PharmEasy's investor slashes its valuation days after Byju's

This markdown has followed PharmEasy's failure to Rs 1,000 crore in equity and its violation of loan covenant terms with Goldman Sachs.

Related Keywords

Neuberger Berman , Janus Henderson , Goldman Sachs , Pine Labs , Pharmeasy , Byjus , Markdown , Evaluation ,